Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7 USD | +1.30% | -4.76% | +22.81% |
May. 30 | Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million | MT |
May. 23 | Oppenheimer Adjusts Price Target on Viracta Therapeutics to $11 From $13, Maintains Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.81% | 27.49M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- VIRX Stock
- News Viracta Therapeutics, Inc.
- Viracta's Lymphoma Drug Candidate Granted European Commission's Orphan Drug Designation